BIOT:SW:SW-L&G Pharma Breakthrough UCITS ETF USD Accumulating ETF (CHF)

ETF | Others |

Last Closing

USD 8.749

Change

-0.01 (-0.08)%

Market Cap

N/A

Volume

2.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XLDX:SW Xtrackers LevDAX Daily Swap UC..

-0.76 (-0.42%)

USD 411,075.38B
XNIF:SW Xtrackers Nifty 50 Swap UCITS ..

+3.10 (+1.33%)

USD 292,109.69B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

+80.00 (+1.10%)

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

+72.00 (+1.48%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

+20.60 (+1.35%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

+43.00 (+2.11%)

USD 134,034.85B
SX7EEX:SW iShares EURO STOXX Banks 30-15..

+0.10 (+0.70%)

USD 6,289.31B
TDXPEX:SW iShares TecDAX® UCITS ETF (DE..

-0.14 (-0.46%)

USD 5,933.97B
SMIEX:SW iShares SLI UCITS ETF (DE)

+0.36 (+0.26%)

USD 5,933.96B
DJSXE:SW iShares Core EURO STOXX 50 UCI..

N/A

USD 5,933.96B

ETFs Containing BIOT:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.65% 17% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.65% 16% F 20% F
Trailing 12 Months  
Capital Gain -16.07% 2% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.07% 2% F 6% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -5.14% 5% F 8% B-
Dividend Return -5.14% 5% F 7% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.55% 38% F 45% F
Risk Adjusted Return -60.17% 3% F 5% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (CHF)

Quarterly Financials (CHF)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.